Last reviewed · How we verify

pegylated IFN alfa-2b plus ribavirin

National Taiwan University Hospital · FDA-approved active Small molecule

pegylated IFN alfa-2b plus ribavirin is a Antiviral combination therapy Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Chronic hepatitis C virus infection.

Pegylated interferon alfa-2b activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.

Pegylated interferon alfa-2b activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication. Used for Chronic hepatitis C virus infection.

At a glance

Generic namepegylated IFN alfa-2b plus ribavirin
SponsorNational Taiwan University Hospital
Drug classAntiviral combination therapy
TargetInterferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase
ModalitySmall molecule
Therapeutic areaVirology/Hepatology
PhaseFDA-approved

Mechanism of action

Pegylated IFN alfa-2b is a long-acting formulation of interferon alfa-2b that binds to interferon-alpha receptors on immune cells, inducing antiviral and antiproliferative effects. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and reduces viral replication. The combination has synergistic activity against hepatitis C virus by enhancing immune clearance and directly suppressing viral replication.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about pegylated IFN alfa-2b plus ribavirin

What is pegylated IFN alfa-2b plus ribavirin?

pegylated IFN alfa-2b plus ribavirin is a Antiviral combination therapy drug developed by National Taiwan University Hospital, indicated for Chronic hepatitis C virus infection.

How does pegylated IFN alfa-2b plus ribavirin work?

Pegylated interferon alfa-2b activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.

What is pegylated IFN alfa-2b plus ribavirin used for?

pegylated IFN alfa-2b plus ribavirin is indicated for Chronic hepatitis C virus infection.

Who makes pegylated IFN alfa-2b plus ribavirin?

pegylated IFN alfa-2b plus ribavirin is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What drug class is pegylated IFN alfa-2b plus ribavirin in?

pegylated IFN alfa-2b plus ribavirin belongs to the Antiviral combination therapy class. See all Antiviral combination therapy drugs at /class/antiviral-combination-therapy.

What development phase is pegylated IFN alfa-2b plus ribavirin in?

pegylated IFN alfa-2b plus ribavirin is FDA-approved (marketed).

What are the side effects of pegylated IFN alfa-2b plus ribavirin?

Common side effects of pegylated IFN alfa-2b plus ribavirin include Flu-like symptoms (fever, fatigue, myalgia), Hemolytic anemia, Neutropenia, Thrombocytopenia, Depression/mood changes, Headache.

What does pegylated IFN alfa-2b plus ribavirin target?

pegylated IFN alfa-2b plus ribavirin targets Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase and is a Antiviral combination therapy.

Related